

Hentschker, Corinna; Wübker, Ansgar

Article — Published Version

Quasi-experimental evidence on the effectiveness of heart attack treatment in Germany

Applied Economics

Provided in Cooperation with:

RWI – Leibniz-Institut für Wirtschaftsforschung, Essen

Suggested Citation: Hentschker, Corinna; Wübker, Ansgar (2020) : Quasi-experimental evidence on the effectiveness of heart attack treatment in Germany, Applied Economics, ISSN 1466-4283, Routledge, Iss. Latest Articles, pp. 1-15, <https://doi.org/10.1080/00036846.2020.1765964>

This Version is available at:

<https://hdl.handle.net/10419/225002>

Standard-Nutzungsbedingungen:

Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Zwecken und zum Privatgebrauch gespeichert und kopiert werden.

Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich machen, vertreiben oder anderweitig nutzen.

Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, gelten abweichend von diesen Nutzungsbedingungen die in der dort genannten Lizenz gewährten Nutzungsrechte.

Terms of use:

Documents in EconStor may be saved and copied for your personal and scholarly purposes.

You are not to copy documents for public or commercial purposes, to exhibit the documents publicly, to make them publicly available on the internet, or to distribute or otherwise use the documents in public.

If the documents have been made available under an Open Content Licence (especially Creative Commons Licences), you may exercise further usage rights as specified in the indicated licence.



<https://creativecommons.org/licenses/by/4.0/>

Quasi-experimental evidence on the effectiveness of heart attack treatment in Germany

Corinna Hentschker* and Ansgar Wübker 

ABSTRACT

Medical technological progress has been shown to be the main driver of health care costs. A key policy question is whether new treatment options are worth the additional costs. In this analysis we assess the causal effect of percutaneous transluminal coronary angioplasty (PTCA), a major new heart attack treatment, on mortality. We use a full sample of administrative hospital data from Germany for the years 2005 to 2007. To account for non-random treatment assignment of PTCA, instrumental variable approaches are implemented that aim to randomize patients into getting PTCA independent of heart attack severity. Instruments include differential distances to PTCA hospitals and regional PTCA rates. Our results suggest a 4.5 absolute percentage point mortality reduction for patients who have access to PTCA compared to patients receiving only conservative treatment. We relate mortality reduction to the additional costs for this treatment and conclude that PTCA treatment is cost-effective in lowering mortality for AMI patients at reasonable cost-effectiveness thresholds.

KEYWORDS

Acute myocardial infarction; instrumental variables; mortality; quasi-experiment

JEL CLASSIFICATION

I11; I18

I. Introduction

Medical technological progress is widespread in health care and has been shown to be the main driver of health care costs (e.g. Cutler and McClellan 2001; Newhouse 1992; Okunade and Murthy 2002). These advances often include implementing new treatment options. Therefore, older treatments coexist with newer treatments for the same disease. New treatments are often more expensive, but their additional benefits are often arguable. A key policy question is whether new treatment options are also more effective, i.e. lead to better outcomes, since health care resources are limited. An overall evaluation of technological progress is not possible, but the single procedures can be assessed.

Acute myocardial infarction (AMI) is well suited for assessing the impact of technological progress of a single procedure, because treatment options for AMI can be clearly divided into ‘old’ and ‘new’ options. AMI occurs when a blood clot blocks a coronary vessel. AMI patients are treated either with thrombolytic drugs (i.e. the ‘old’ treatment) to dissolve the blood clot or with revascularization techniques (i.e. the ‘new’ treatment). Revascularization

(REVAS) encompasses coronary artery bypass graft surgery (CABG) and percutaneous transluminal coronary angioplasty (PTCA).

This paper investigates whether new AMI treatment options reduce mortality compared to a conservative therapy. Assessing treatment options for AMI patients is of interest for several reasons. First, AMI treatment has substantial welfare implications because AMI displays high mortality rates and treating it can substantially extend life. Second, assessing AMI patients allows us to focus on a large part of the health system, as AMI is one of the most common reasons for hospital admissions in countries like the US or Germany. In the year 2015, nearly 51,000 people (6% of all deaths) died from acute myocardial infarction (AMI) in Germany (Statistisches Bundesamt, 2017). Although a decline in deaths is observable – in 2002 over 69,000 people died from a heart attack – AMI remains one of the most common causes of death in Germany. In the US, heart diseases are the leading cause of death, too. In 2015 114,000 people (4% of all deaths) died from AMI in the United States (Centrer for Disease Control and

CONTACT Ansgar Wübker  ansgar.wuebker@rwi-essen.de.

*Corinna Hentschker, RWI –Leibniz Institute for Economic Research and Leibniz Science Campus Ruhr; Ansgar Wübker, RWI –Leibniz Institute for Economic Research, Ruhr-University Bochum and Leibniz Science Campus Ruhr. –We thank Thomas Bauer, Dörte Heger, Maryna Ivets, Martin Salm, Hendrik Schmitz, Leonie Sundmacher, and Amelie Wuppermann for valuable suggestions. Moreover, we are grateful for comments at the Spring Meeting of Young Economists (Ghent), the Tilburg Research Seminar and the Annual Workshop of the Econometrics Committee of the dggö(Essen). Funding by the Leibniz Science Campus Ruhr is gratefully acknowledged. –All correspondence to: Ansgar Wübker, RWI, Hohenzollernstr. 1-3, 45128 Essen, Germany, e-mail: ansgar.wuebker@rwi-essen.de.

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Prevention – National Center for Health Statistics, 2017). The German population which is considered in this paper is large enough to detect even small impacts of the treatment on hospital mortality. Third, application of AMI treatments displays strong regional differences. This regional variation in health care use might reflect inefficiencies if they do not mirror differences in medical need (Skinner 2011). Fourth, there is a lack of evidence on the effectiveness of AMI treatment options. Although randomized controlled trials provide evidence for the effectiveness of REVAS (Keeley, Boura, and Grines 2003), there are only a few quasi-experimental studies (Stukel et al. 2007; McClellan, McNeil, and Newhouse 1994; Cutler and McClellan 2001; Sanwald and Schober 2017) which assess whether this effectiveness is practically realized, i.e. whether external validity exists. We discuss how we extend these studies below.

There are empirical challenges to this analysis: patients who get invasive treatment options are not directly comparable to patients who get conservative treatment. The first group is often younger and healthier, may have lower AMI severity and may differ in unobserved factors from patients who do not get the invasive treatment. Differences in outcomes among AMI patients who are treated differently may be attributable to unobserved factors, resulting in biased estimates of the effectiveness of alternative treatments outside randomized controlled trials (McClellan, McNeil, and Newhouse 1994). In consequence, existing observational studies have used instrumental variable techniques to attempt to identify patients who are similar in terms of health status and other unobserved factors but who for some reason receive different AMI treatment.

We follow the instrumental variable (IV) approach introduced by McClellan, McNeil, and Newhouse (1994). The authors use the difference between the distance of the closest hospital offering invasive treatment options to the patient and the closest hospital treating AMI patients regardless of whether invasive treatments are available (differential distance) as instrument. The authors find a 5-percentage point (pp) reduction in mortality, but this reduction occurs already prior to the REVAS intervention which is reflected in the

1-day mortality. The authors therefore conclude that reduced mortality is not due to REVAS, but is instead attributable to high-volume hospitals that – in addition to offering REVAS – generally have better facilities. Cutler (2007) uses the same instrument and Medicare data as McClellan, McNeil, and Newhouse (1994). He has the advantage of being able to follow patients for up to 17 years, but only those AMI patients admitted in 1986–1988. He finds an one year additional life expectancy for REVAS patients at a cost of around 40,000 USD and concludes that REVAS is highly cost-effective. Sanwald and Schober (2017) examine the effect for patient’s treatment at a PTCA hospital with an Austrian dataset from 2002 to 2011. They find a 9.5 pp reduction in 3-year mortality for patients treated in a PTCA hospital. Stukel et al. (2007) use a slightly different approach, i.e. they take regional REVAS rates as instrument.

We contribute to the literature in the following ways: We are the first to execute the analysis with German data. Ethnic, geographic, and socioeconomic characteristics differ markedly between countries, and, hence, the effect of REVAS could also differ between countries. Second, we are the first who use comprehensive data from the unselected, complete hospital population of an industrialized nation to analyse the impact of PTCA treatment. Studies from the US can often only use Medicare data which only includes patients older than 64 years (e.g. McClellan, McNeil, and Newhouse 1994; Stukel et al. 2007). Third, existing literature uses data from 1995 and older; since that time REVAS techniques have likely improved, and more patients are treated with REVAS (see Appendix B for further details). One exception is the study of Sanwald and Schober (2017) who use data from 2002 to 2011 but with a much smaller sample size and a different focus, namely on the effect of an admission to a hospital with a catheterization laboratory. Additionally, we shed some light on the issue whether the REVAS effect comes from the procedure itself or from the higher case volume. Finally, we conduct cost-effectiveness exercise that contributes to the literature analysing whether technological change in heart attack treatment is worth it (Cutler and McClellan 2001).

The remainder of this paper is organized as follows: Section 2 provides an overview of the data and descriptive statistics. The empirical approach is described in section 3, followed by the results in section 4. Section 5 concludes.

II. Data

We use a full sample of all hospital inpatients in Germany from 2005 to 2007. It is an administrative data set which must be generated by every hospital for insurance billing purposes according to German law requirements (§21 KHEntgG; hospital remuneration law). The data set includes patient characteristics, e.g. age, sex, admission and discharge date, main and secondary diagnoses and procedure codes, and the ZIP code of the patient's residence. The data set also contains hospital characteristics, e.g. hospital identifier, ownership type, and whether it is a university hospital. The hospital identifier allows us to add the address of the hospital from another data source. Because we only have patient resident ZIP codes, we geo-coded the hospital addresses and the centroids of the ZIP codes and calculate the distance for every ZIP code to the chosen hospital and to the surrounding hospitals.

We focus on patients with AMI. AMI is an acute event characterized by an interruption of blood flow to a part of the heart due to the occlusion of arteries. The main goal of treatment is to limit immediate damage to the heart by restoring blood flow and providing the heart muscle with adequate oxygen as soon as possible. There are three options for treating AMI patients. Medical management often includes thrombolytic drugs, alongside with supportive care, to dissolve blood clots caused by AMI. An alternative to thrombolysis is using surgery. REVAS encompasses CABG and PTCA. The main difference between CABG and PTCA is that PTCA is a minimally invasive procedure and CABG is an open-heart surgery. CABG is less common than PTCA or thrombolytic drugs (Steg et al. 2012). CABG and PTCA are preceded by cardiac catheterization, a diagnostic

procedure to identify the affected artery (compare Appendix B for further background information).

We use diagnosis and procedure codes from a German definition handbook for inpatient quality indicators (Mansky et al. 2011). We include patients who are coded with the main diagnosis of a ST-elevated myocardial infarction (STEMI, diagnosis codes I21.0–I21.2) or a Non-ST-elevated myocardial infarction (NSTEMI, diagnosis code I21.3). Patients with a subsequent MI or unspecified MI are not included. Based on the procedure codes we can determine the invasive treatment options, i.e. whether the patient received a PTCA or a CABG. In the final sample, we do not include patients with a CABG ($N = 27,128$). PTCA and CABG are both invasive treatments for the heart attack treatment but only 5% of the patients get a CABG. To determine the single effect of PTCA compared to medical treatment instead of the mixed effect of PTCA and CABG compared to medical treatment we exclude CABG patients.

Further exclusions are as follows: Patients under the age of 19 are excluded ($N = 54$). We delete patients with missing patient characteristics ($N = 589$) and patients with invalid ZIP codes ($N = 6,816$). We also exclude patients with a travel time exceeding 60 minutes to the chosen hospital ($N = 15,488$). It is unlikely that these patients had their heart attack at home but were on holiday, travelling etc. We exclude patients who have an ambulatory status and do not stay in the hospital ($N = 1,408$). We further remove patients who are coded with transfer as the reason for discharge ($N = 126,455$). This means that they were transferred to another hospital after their hospital stay. For the transferring hospital we cannot measure the outcome of the patient. We drop patients who are treated in hospitals with less than 10 cases ($N = 1,719$). We assume that these hospitals do not treat AMI patients and, therefore, do not belong in the sample. We end up with a sample of 406,281 patients treated in 1,292 hospitals.¹

The main variable of interest is PTCA which is specified as 1 if the patient received a PTCA and 0 if

¹Generally, we observe a unique identifier for hospitals in our data set but for some hospitals the identifier stands for two or more hospital locations. In this case, we checked which location offers AMI treatment at all and in case two or more locations offer AMI treatment, we assign the patients to the closest hospital location. With this procedure we ended up with 30 more hospitals in the data set than without splitting the hospital locations. The results remain essentially the same when we compare results with and without splitting the hospital locations.

not. As outcome measure, we use in-hospital mortality. We extract this information from the variable discharge reason which can have the following main specifications: treatment ended regularly, discharge to nursing home or rehab hospital, or death.² We recoded this variable as mortality which is 1 if patient died in hospital and 0 otherwise. In-hospital mortality of AMI patients is a widely used outcome parameter (e.g. Cutler 2007; McClellan, McNeil, and Newhouse 1994). Unfortunately, we cannot track patients after their hospital stay and hence, it is not possible for us to use for example 30-day-mortality as outcome measure.

We define a PTCA hospital as a hospital which treats more than 10 patients with PTCA per year.³ Using this definition we can calculate the distances from the patient's residence ZIP code to the closest hospital which treats AMI patients and the closest PTCA hospital. We calculate the difference of both variables which we use as an instrument (see Section 3).

The decision whether a patient receives a PTCA is not independent from other health characteristics which also influence the outcome. For this reason, we control for further patient characteristics. We include age, sex, and admission reason. We include a binary variable whether the admission was on a weekend or holiday, and a binary variable whether the admission was at night. These variables should capture the effect of 'off-hour' admission because some literature has found that the mortality risk can increase during this time (Bell and Redelmeier, 2001; Hentschker 2016). We use the Charlson Comorbidity Index (CCI) to control for further comorbidities besides the AMI (Charlson et al. 1987). The CCI consists of 17 comorbidities which are coded as binary variables. The first Charlson diagnosis is myocardial infarction. We set this diagnosis to '0' because all our patients have it as main diagnosis. To construct the index, the comorbidities are weighted and summed up. The higher the index number, the more ill the patient is besides the main diagnosis of AMI.

Due to the different mortality rates of the two AMI types, we add a control variable for AMI type, which is 1 if the patient has a NSTEMI and 0 if the patient has a STEMI. We add a binary variable 'city'

which indicates whether patients live in an urban or rural area. We also include year dummies to capture any changes during the years. At the hospital level we control for ownership type (public, not-for-profit or for-profit), and university hospital.

We add federal state control variables to capture differences between federal states. We include purchasing power per inhabitant and the unemployment rate in every ZIP code of the year 2005 (Budde and Eilers 2014; Microm Micromarketing-Systeme und Consult GmbH 2015b, 2015c, 2015a; Microm Consumer Marketing 2014). These two variables capture socioeconomic differences between ZIP codes. Additionally, we include the minimum time to an AMI hospital to control for further structural differences between ZIP codes.

Table 1 shows descriptive statistics for the whole sample and the sample divided by the method of treatment, i.e. whether the patient receives a PTCA or not. 48% of all patients in our sample receive a PTCA. The average unadjusted mortality rate is 12.3%. It is 6.3% for patients who receive a PTCA and 17.9% for patients without. Patients are on average 70 years old. Patients who get a PTCA have an average age of 65 and, hence, they are nearly nine years younger than patients who do not get a PTCA. On average 8% of the patients have a CCI of 5 or higher. This share is much lower in the group of patients who get a PTCA (4.0%) compared to patients who do not get a PTCA (11.4%).

III. Methods

To measure the effect of PTCA on mortality, we regress our binary outcome variable, y_{ih} , 'death', which is 1 if patient i died in hospital h , on a binary variable, $PTCA_{ih}$, which indicates whether the patient received a PTCA (1) or not (0). We also control for further patient characteristics, x_{ih} , and hospital characteristics, k_h . The specification is shown in equation (1). We estimate the equation on patient level. Standard errors are clustered at the hospital level.

²Another specification of the variable discharge reason is 'discharge to another hospital' but these patients have been excluded beforehand.

³We also defined a PTCA hospital with 5, 24 (i.e. 2 PTCA per month), and 48 cases (i.e. 4 PTCA per month) per year. The results do not change.

Table 1. Descriptive statistics of AMI patients.

	All Patients		Patients with PTCA		Patients w/o PTCA		Difference (5)-(3)
	Mean (1)	SD (2)	Mean (3)	SD (4)	Mean (5)	SD (6)	
Dependent variable							
Mortality	0.123	0.329	0.063	0.243	0.179	0.384	0.116***
Endogenous regressor							
PTCA	0.482	0.500	1.000	0.000	0.000	0.000	
Instrument							
Differential time	6.232	9.063	4.270	7.451	8.055	9.999	3.785***
Control variables							
Age	69.717	13.436	65.171	12.483	73.942	12.901	8.770***
Male	0.614	0.487	0.709	0.454	0.527	0.499	-0.182***
Admission reason: Emergency	0.639	0.480	0.657	0.475	0.621	0.485	-0.036***
Admission reason: Transfer	0.099	0.299	0.099	0.298	0.100	0.300	0.001
Non-ST-elevated MI	0.488	0.500	0.376	0.485	0.591	0.492	0.215***
CCI: 1-2	0.401	0.490	0.399	0.490	0.404	0.491	0.005***
CCI: 3-4	0.175	0.380	0.117	0.321	0.229	0.420	0.112***
CCI: ≥5	0.079	0.269	0.040	0.197	0.114	0.318	0.074***
Winter	0.339	0.473	0.333	0.471	0.344	0.475	0.011***
Weekend/holiday admission	0.245	0.430	0.233	0.423	0.256	0.437	0.023***
Night admission	0.248	0.432	0.241	0.428	0.254	0.436	0.013***
City	0.723	0.447	0.736	0.441	0.711	0.453	-0.025***
Year 2006	0.330	0.470	0.332	0.471	0.329	0.470	-0.004**
Year 2007	0.351	0.477	0.365	0.481	0.338	0.473	-0.026***
Ownership: not-for-profit	0.351	0.477	0.290	0.454	0.408	0.492	0.118***
Ownership: for-profit	0.144	0.351	0.161	0.367	0.128	0.334	-0.033***
University hospital	0.095	0.294	0.150	0.357	0.044	0.206	-0.106***
Minimum time to hospital	10.649	6.331	10.820	6.359	10.489	6.300	-0.331***
Purchasing power per inhabitant	18.370	3.990	18.564	4.133	18.189	3.844	-0.375***
Unemployment rate	8.507	4.594	8.508	4.708	8.507	4.486	-0.002
Number of patients	406.281		195.705		210.576		

Note: We control also for different federal states. * $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$. CCI – Charlson Comorbidity Index.

$$y_{ih} = \alpha_0 + \beta_1 PTCA_{ih} + \mathbf{x}'_{ih} \beta_A + \mathbf{k}'_h \beta_A + \varepsilon_{ih} \quad (1)$$

Our administrative data set has detailed information on patient characteristics. Nevertheless, detailed socioeconomic characteristic and clinical parameters are missing. Hence, we cannot assume that we are able to control for all patient characteristics that are correlated with the decision whether a patient receives a PTCA or not. The reason for this is that patient groups with and without PTCA differ significantly, e.g. patients who receive PTCA are younger and healthier and therefore have a lower risk of death (see Table 1). The patient selection bias may occur not only in observable but also in unobservable characteristics which are captured in the error term. If unobserved healthier patients get the PTCA who inherently also have a lower mortality rate, this will lead to an overestimation of the PTCA effect in absolute terms.

To exclude problems with unobserved patient heterogeneity we use an instrumental variable (IV) approach. Therefore, we need an instrument which

is highly correlated with the likelihood of receiving a PTCA but has no effect on mortality. We follow the work of McClellan, McNeil, and Newhouse (1994) and Newhouse and McClellan (1998) who estimate the local average treatment effect of undergoing REVAS. The authors showed that the differential distance between the nearest REVAS hospital and the nearest hospital was strongly correlated with the probability of getting a PTCA treatment but uncorrelated with observable indicators of quality. The differential distance has become a widely applied instrument to study different treatment effects in medical care (Gowrisankaran and Town 1999; Khwaja et al. 2011).

We use differential time as a continuous instrument and define it as the driving time to the closest PTCA hospital minus the driving time to the closest hospital which offers AMI treatment. For this instrument it is irrelevant which hospital the patient has chosen in reality. The differential time is 0 if the closest hospital is already a PTCA hospital and greater than 0 if the closest hospital offers no PTCA

Table 2. Descriptive statistics by differential time.

Differential time	0 min		> 0 min		Differences
	Mean	SD	Mean	SD	
Mortality	0.119	0.324	0.126	0.332	0.007***
PTCA	0.579	0.494	0.398	0.489	-0.181***
Differential time	0.000	0.000	11.578	9.524	11.578***
Age	69.587	13.470	69.828	13.406	0.241***
Male	0.618	0.486	0.612	0.487	-0.006***
Admission reason: Emergency	0.695	0.460	0.590	0.492	-0.105***
Admission reason: Transfer	0.054	0.227	0.138	0.345	0.083***
Non-ST-elevated MI	0.487	0.500	0.489	0.500	0.002
CCI: 1–2	0.399	0.490	0.404	0.491	-0.005***
CCI: 3–4	0.174	0.380	0.175	0.380	0.001
CCI: ≥ 5	0.077	0.266	0.080	0.272	0.004***
Winter	0.339	0.473	0.338	0.473	-0.001
Weekend/holiday admission	0.252	0.434	0.240	0.427	-0.013***
Night admission	0.261	0.439	0.237	0.425	-0.024***
City	0.757	0.429	0.695	0.461	-0.062***
Year 2006	0.336	0.472	0.326	0.469	-0.010***
Year 2007	0.368	0.482	0.337	0.473	-0.031***
Ownership: not-for-profit	0.323	0.468	0.375	0.484	0.053***
Ownership: for-profit	0.141	0.348	0.146	0.353	0.004***
University hospital	0.094	0.291	0.097	0.295	0.003***
Minimum time to hospital	10.456	6.152	10.815	6.475	0.359***
Purchasing power per inhabitant	18.988	4.279	17.840	3.642	-1.148***
Unemployment rate	8.781	4.750	8.273	4.442	-0.508***
Number of patients	187.596		218.685		

Note: We control also for different federal states. * $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$. CCI – Charlson Comorbidity Index.

treatment option. Figure A1 in Appendix A shows how the differential distance varies within Germany and a descriptive statistic by differential time is shown in Table 2. Therefore, we build two groups; the first group has a differential time of 0 and the second group has a differential time greater than 0. The instrument should divide the patients into two groups which should not differ in their patient characteristics but in the probability of receiving a PTCA. It is perceivable that the first group has a slightly lower unadjusted probability of death and has a higher share of patients who receive a PTCA (57.9% vs. 39.8%), i.e. patients who have a PTCA hospital as the closest hospital have an 18 pp higher likelihood to receive a PTCA than patients who live further away. The minimum time to a hospital which treats AMI patients is still similar for both groups (10.5 and 10.8 minutes) but the minimum time to a PTCA hospital is much higher for the second group (22.4 minutes). Hence, it is obvious that the differential distance is a crucial factor whether the patient is treated in a PTCA hospital and receives a PTCA.

Differential time is a valid instrument if patients do not choose their place of residence based on the availability of hospital resources. This is not a testable criterion, but Table 2 shows that the characteristics of patients who live close

to a PTCA hospital and patients who live further away are balanced. This is also assumed for the unobservable characteristics. Due to the large sample size the differences between the patient characteristics are nearly all statistically significant but the magnitudes of the differences are rather small. One exception is the distribution of urban and rural residence with a difference of more than 5%. This difference is rather caused by different hospital structures in rural and urban areas. The second exception is the different distribution of admission reason. On the one hand, this is a coding issue, because AMI patients are generally emergency cases and, in our data, set it is only possible to account for administrative emergencies, i.e. all patients are coded as emergencies if they reached the hospital without a doctor's referral. This is not comparable to a medical emergency. On the other hand, patients with admission reason transfer are usually patients who are transferred to a PTCA hospital. Patients who have as closest hospital a PTCA hospital need no transfer into a PTCA hospital. We account for the differences in admission status and rural and urban areas by including the variables in the regression and execute separate regressions for each group in robustness checks.

The second requirement for a valid instrument is that the instrument must not be correlated with another (unobserved) variable which is also correlated with the outcome. For example, if PTCA hospitals are also better in the follow-up care of patients, the effect of PTCA is still overestimated in absolute terms (Cutler 2007).

We apply the IV regression in the established two-step procedure. In the first-stage equation (equation (2)), we regress our endogenous variable PTCA on all covariates and our instrument differential time (DT). In the second-stage equation (equation (3)), we use the fitted values of PTCA from equation (2) to estimate the causal effect of PTCA on mortality. Standard errors are clustered at the hospital level.

$$PTCA_{ih} = \pi_0 + \mathbf{x}'_{ih}\boldsymbol{\pi}_1 + \mathbf{k}'_h\boldsymbol{\pi}_2 + \gamma_2 DT_{ih} + v_{ih} \quad (2)$$

$$Y_{ih} = \alpha_0 + \beta_2 PTCA_{ih} + \mathbf{x}'_{ih}\boldsymbol{\beta}_B + \mathbf{k}'_h\boldsymbol{\beta}_B + \varepsilon_{ih} \quad (3)$$

With IV regression we only measure a local average treatment effect (LATE) (Imbens and Angrist 1994). In our case, it is the effect for patients who receive a PTCA because they live close to a PTCA hospital but would not get a PTCA if they lived further away (compliers).

IV. Results

Regression coefficients of the linear probability model (LPM) are shown in Table 3. The complete regression results are shown in Table A1 in Appendix A. In a bivariate regression of PTCA on mortality (model (1)) we find an 11.7 pp reduction in mortality for PTCA patients compared to patients with a conservative therapy. If we add further patient and hospital characteristics the

Table 3. Regression results.

a) LPM				
	(1)	(2)	(3)	(4)
PTCA	-0.1165*** (0.0023)	-0.0983*** (0.0025)	-0.1023*** (0.0023)	-0.1019*** (0.0023)
Patient characteristics	No	Yes	Yes	Yes
Hospital characteristics	No	No	Yes	Yes
Socioeconomic characteristics	No	No	No	Yes
Federal state indicators	No	No	No	Yes
R-squared	0.031	0.091	0.092	0.093
Number of patients	406,281	406,281	406,281	406,281
Number of hospitals	1,292	1,292	1,292	1,292
b) IV (instrument: differential time)				
	(5)	(6)	(7)	(8)
PTCA	-0.0454*** (0.0100)	-0.0486*** (0.0088)	-0.0504*** (0.0089)	-0.0451*** (0.0098)
Patient characteristics	No	Yes	Yes	Yes
Hospital characteristics	No	No	Yes	Yes
Socioeconomic characteristics	No	No	No	Yes
Federal state indicators	No	No	No	Yes
R-squared	0.020	0.086	0.087	0.087
First-stage F-statistic	210.081	281.658	349.745	352.852
Test for endogeneity (p-value)	0.000	0.000	0.000	0.000
Number of patients	406,281	406,281	406,281	406,281
Number of hospitals	1,292	1,292	1,292	1,292
c) IV (instrument: share of PTCA patients)				
	(9)	(10)	(11)	(12)
PTCA	-0.0575*** (0.0056)	-0.0570*** (0.0058)	-0.0606*** (0.0061)	-0.0480*** (0.0058)
Patient characteristics	No	Yes	Yes	Yes
Hospital characteristics	No	No	Yes	Yes
Federal state indicators	No	No	No	Yes
Socioeconomic/structural indicators	No	No	No	Yes
R-squared	0.023	0.088	0.088	0.087
First-stage F-statistic	1305.759	1349.476	1165.124	1498.715
Test for endogeneity (p-value)	0.000	0.000	0.000	0.000
Number of patients	406,281	406,281	406,281	406,281
Number of hospitals	1,292	1,292	1,292	1,292

Notes: Clustered standard errors (at the hospital level) in parantheses; * p < 0.10, ** p < 0.05, *** p < 0.01.

effect slightly decreases to 10.2 pp (model (4)). Because of unobserved patient characteristics the OLS coefficients are biased and, hence, we turn to our IV results. Our instrument differential time highly correlates with our endogenous variable PTCA. The first-stage F-statistic is 353 if we use the model with all covariates (model (8)). Further, we can reject the null hypothesis of the Durbin-Wu-Hausman test that PTCA is exogenous ($p < 0.01$). Hence, we conclude that IV regression is necessary, and we have a strong instrument.

The IV coefficients are smaller in absolute terms than the OLS coefficients. Even though the coefficients are not directly comparable because they measure different treatment effects (ATT vs. LATE), the reduction in absolute terms is in line with the basic idea that unobserved patient characteristics may influence the PTCA treatment decision. If (unobserved) healthier patients get a PTCA, the PTCA coefficient will decrease in absolute terms in an IV specification. In the bivariate specification, we find a 4.5 pp reduction in mortality for PTCA patients (model (5)). After adding the covariates, the effect of PTCA on mortality stays constant at 4.5 pp (model (8)).

In a robustness check we also use a similar instrument to Stukel et al. (2007), i.e. the regional

PTCA rates. We specify the instrument as the share of PTCA patients in a 4-digit ZIP code area. Regional PTCA rates may serve as an effective instrumental variable because prognostic factors for AMI mortality, such as mean AMI severity, are similar between regions that have very different PTCA rates. Additionally, in Appendix B we demonstrate that there is much variation in PTCA rates across German regions establishing that the range of variation spanned by the IV approximates the average effect in the population quite well (Newhouse and McClellan 1998). The causal effect of PTCA in this IV specification is a 4.8 pp reduction in mortality in the full model (Table 3, model (12)). Even though this is slightly higher than the effect obtained when using differential time as instrument, there is no statistically significant difference between the two effects. This is investigated with a tentative test that checks whether the coefficient of one instrument lies within the 95% confidence interval of the other instrument.

To get more specific insights in the PTCA effectiveness, we split the sample into different subgroups (Table 4). In Table 4 every regression includes all covariates of the full model of Table 3. Due to different availability of rescue services and

Table 4. Robustness regressions for different subgroups.

	OLS		IV		First-stage	Test for endogen.	Number of patients	Number of hospitals
	Coefficient	S.E.	Coefficient	S.E.	F-statistic	(p-value)		
<i>Basic model</i>	-0.1019 ***	0.0023	-0.0451 ***	0.0098	352.8525	0.0000	406.281	1.292
<i>Regional area</i>								
Rural area	-0.0990 ***	0.0038	-0.0766 ***	0.0169	200.4305	0.1828	112.440	799
Urban area	-0.1035 ***	0.0026	-0.0213 **	0.0108	211.8138	0.0000	293.841	1.137
<i>Admission status</i>								
Emergency	-0.1284 ***	0.0027	-0.0581 ***	0.0106	569.8578	0.0000	259.399	1.256
w/o Transfers	-0.1152 ***	0.0023	-0.0534 ***	0.0092	545.7250	0.0000	365.961	1.286
<i>Admission time</i>								
Day time	-0.0980 ***	0.0023	-0.0458 ***	0.0103	295.7826	0.0000	305.450	1.292
Night time	-0.1166 ***	0.0032	-0.0464 ***	0.0141	523.5723	0.0000	100.831	1.261
<i>Age</i>								
Age < 65 years	-0.0563 ***	0.0022	-0.0206 ***	0.0071	261.6932	0.0000	129.471	1.254
Age ≥ 65 years	-0.1158 ***	0.0027	-0.0541 ***	0.0134	378.9362	0.0000	276.810	1.292
<i>AMI type</i>								
Non-ST-elevated MI	-0.0592 ***	0.0018	-0.0219 *	0.0127	291.3082	0.0045	198.174	1.290
ST-elevated MI	-0.1440 ***	0.0036	-0.0576 ***	0.0115	349.6927	0.0000	208.107	1.292
<i>Case volume</i>								
Case volume < 400 cases	-0.1031 ***	0.0024	-0.0387 ***	0.0092	519.7764	0.0000	332.583	1.261
Case volume < 350 cases	-0.1022 ***	0.0025	-0.0380 ***	0.0091	591.0795	0.0000	301.457	1.239
Case volume < 300 cases	-0.1006 ***	0.0026	-0.0359 ***	0.0093	611.0190	0.0000	265.729	1.208
Case volume < 250 cases	-0.0981 ***	0.0028	-0.0390 ***	0.0094	642.9564	0.0000	225.682	1.168
Case volume < 200 cases	-0.0955 ***	0.0033	-0.0278 ***	0.0105	561.8094	0.0000	186.862	1.109
Case volume < 150 cases	-0.0970 ***	0.0038	-0.0131	0.0146	363.3696	0.0000	146.892	1.038
<i>Placebo regression</i>			-0.1353	0.2925	6.7857	0.9090	406.281	1.292

Notes: Clustered standard errors (at the hospital level) used; * $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$. All regressions are estimated with all covariates of the full standard regression model.

PTCA possibilities in urban and rural areas, we specify different regressions for these regions to rule out the possibility that the PTCA effect is only driven by PTCA hospitals in cities. Patients living in rural areas benefit even more from a PTCA than patients living in urban areas. This could be because that the differential time differs between urban and rural areas and has a higher variance in rural areas. In our sample we have patients with different admission statuses, namely regular admissions, emergencies and transfers from other hospitals. As outlined in Section 3 we can only distinguish administrative emergencies but no medical emergencies. Nevertheless, we specified a regression only with coded emergency cases. The PTCA effect increases in absolute terms. Patients with admission reason transfer have been treated in two hospitals. In a robustness check we exclude these patients from the sample. The PTCA effect also increases in this case. For both regressions on the admission status the conclusions drawn from the main results remain the same. For the effectiveness of PTCA it does not matter whether the patient has been admitted at day or night time – the coefficients of PTCA for day and night are nearly identical. Our instrument differential time uses the patient's residence ZIP code to calculate the

distance to the hospitals. During the day it may be the case that the patient is not at home when the heart attack occurs, and, hence, there might be a measurement error in the instrumental variable. At night it is more likely that the patient is at home. As both coefficients are comparable, we rule out the possibility of a measurement error in our instrumental variable during the day. The advantage of PTCA is greater for patients over the age of 65. The reason for this is that younger patients may have less severe heart attacks and the benefit of PTCA is less important. A diverse effect is identified for different AMI types. Patients with a ST-elevated myocardial infarction benefit much more from a PTCA than patients with a Non-ST-elevated myocardial infarction.

Former literature (McClellan, McNeil, and Newhouse 1994) could not detect whether the PTCA effect comes from the procedure itself or whether it is for example hospital's case volume or hospital's specialization. We want to shed some light on this issue. Figure 1 shows the distribution of hospital case volume for all hospitals and separately for hospitals with and without PTCA possibility. It is obvious that PTCA hospitals treat much more patients in general, i.e. there are only a few hospitals above 250 cases per year which do not offer PTCA treatment. This is one reason why the




Figure 1. Distribution of case volume.

effect of PTCA and case volume are difficult to separate. We want to check whether the PTCA effect also exists in hospitals with lower case volumes. We specify a regression for patients treated in hospitals with less than 400 cases up to a case volume with less than 150 cases. The effect of PTCA decreases if the hospitals with the highest case volume are excluded from the sample but the effects are still highly significant (Table 4). For hospitals with a case volume below 150 cases, the PTCA effect becomes insignificant. Taken together, it can therefore be concluded that the PTCA effect is not only driven by hospitals with the highest case volume.

As another robustness check we follow Bound, Jaeger, and Baker (1995) and do a placebo regression. Therefore, we randomly assign our instrument values to the patients. Hence, the instrument should have no explanatory power for the endogenous variable. Our first-stage F-statistic reduces below one and the results do change completely.

We find a 4.5 pp reduction in mortality for patients treated with PTCA. This is a sizable effect. Nevertheless, the additional PTCA costs must be in an appropriate proportion to these benefits. Due to the limited resources in the health system it is necessary to spend money only on treatments which have an adequate cost-benefit ratio. Therefore, we calculate the minimum number of years which a patient must live in perfect health to make PTCA cost-effective. We have 195,705 patients who get a PTCA in our sample during 2005 and 2007. 8,826 deaths are avoided through this intervention. PTCA costs are € 1,600 above the costs of conservative treatment. This amounts to € 315 million in additional costs for all PTCA patients within this period.⁴

For the calculation, a value of a quality adjusted life year (QALY) has to be assigned. The thresholds are between 50 USD,000 to 100 USD,000 (approx. € 35,700 to € 71,400⁵) in the US and between £ 20,000 to £ 30,000 (approx. € 28,500 to € 42,800) in the UK (Ryen and Svensson 2015). The total benefit of the PTCA results from the multiplication of the number of avoided deaths, the value of a QALY and the

additional number of years lived. The benefit must be higher than the additional costs. Therefore, we calculate the minimum number of years lived in perfect health to make PTCA cost-effective and set the PTCA benefit equal to the additional PTCA costs. The PTCA patients must therefore live at minimum 0.5 to 1.2 additional years in perfect health so that PTCA is cost-effective. Cutler (2007) finds that PTCA patients have a 1.1 years additional life expectancy. Hence, our results indicate that PTCA is also a cost-effective intervention. Additionally, we differentiate cost effectiveness by age. Due to the fact, that the advantage of PTCA is greater in terms of health benefits for patients over the age of 65, they have to live at minimum only 0.4 to 1.0 additional years in perfect health to let PTCA be cost effective. Patients younger than 65 years have to live 1.1 to 2.7 years at minimum in perfect health to let PTCA be cost effective.

V. Conclusion

This paper investigates whether the use of new treatments (i.e. PTCA) for AMI leads to a reduction in mortality compared to conservative/old therapy. We use administrative hospital data of a full sample of all inpatients in Germany from 2005 to 2007. Due to the challenge of unobserved patient heterogeneity we use an instrumental variable approach. As an instrument we use the differential time of the closest hospital to the patient offering PTCA treatment and the closest hospital treating AMI patients regardless of whether PTCA treatment is available in our basic specification. We find a 4.5 pp reduction in mortality for patients receiving PTCA treatment compared to conservative treatment. We measure the effect for AMI patients who receive a PTCA because they live relatively close to a PTCA hospital but who would not have gotten a PTCA had they lived further away (local average treatment effect). These estimates on the marginal returns to care are the most relevant ones because they give the effect for people who would be affected by a policy decision (Almond et al. 2010).

⁴For 2007, we have accounting data for the AMI patients available. We take the weighted average for patients with and without PTCA which results in € 1,600 additional costs for PTCA. This is 1.4 times higher than treatment without PTCA and comparable with the study of Soekhlal et al. (2013) in the Netherlands.

⁵We use exchange rates of the year 2007, i.e. for the 1 USD 4 per euro and for the UK £ 0.7 per euro.

In a robustness check, we apply another IV specification and measure the treatment effect of an alternative population, defined as patients who get a PTCA in regions with higher PTCA rates but would not have gotten a PTCA in regions with lower PTCA rates. The regional IV predicts a wide range of PTCA rates, as the share of PTCA procedures for AMI treatment is below 35% in some regions and above 65% in others. For this IV approach we find a 4.8 pp reduction in mortality for patients who were treated with PTCA compared to conservative therapy in the most conservative specification. This effect is similar to the effect in our main specification. In contrast to McClellan, McNeil, and Newhouse (1994), we find that the PTCA effect is not only driven by hospitals with the highest case volume. This might reflect the improvement of PTCA techniques and that PTCA is performed sooner after hospital admission than in the past. Both aspects are associated with lower mortality rates (Steg et al. 2012; Krumholz et al. 2011; Rathore et al. 2009).

It cannot completely be ruled out that the PTCA effect includes other factors which are better within PTCA hospitals and lead to a better outcome, e.g. the follow-up care of patients. The effect of PTCA would then decrease. Nevertheless, our robustness checks indicate that the procedure itself substantially contributes to the treatment outcome.

What policy conclusions can be drawn from our results? To answer this question, one needs to keep in mind that our IV estimates only reflect the effect for patients who are affected by the instrument and need a careful interpretation as discussed above. Our results suggest the diffusion of PTCA treatment in Germany may be worthwhile and that providing patients' access to PTCA could be beneficial. Applying simple back-of-the-envelope calculations, we find that PTCA is cost-effective at reasonable cost-effectiveness thresholds, if the patients live for a minimum of 0.5 to 1.2 years in perfect health after the PTCA.

While we show that PTCA affects AMI mortality during a hospital stay, we cannot assess mortality and cost effects over longer time horizons as we only have inpatient hospital data available and cannot track patients after their hospital stay. Whether or not there are long-run effect of PTCA-treatment on

outcomes and costs of care in Germany, is an interesting topic for future research.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was supported by the Leibniz-Gemeinschaft [0].

References

- Almond, D., J. J. Doyle, Jr., A. E. Kowalski, and H. Williams. 2010. "Estimating Marginal Returns to Medical Care: Evidence from At-Risk Newborns." *The Quarterly Journal of Economics* 125 (2): 591–634. doi:10.1162/qjec.2010.125.2.591.
- Bell, C. M., and D. A. Redelmeier. 2001. "Mortality among Patients Admitted to Hospitals on Weekends as Compared with Weekdays." *The New England Journal of Medicine* 345 (9): 663–668. doi:10.1056/NEJMs003376.
- Bound, J., D. A. Jaeger, and R. M. Baker. 1995. "Problems with Instrumental Variables Estimation When the Correlation between the Instruments and the Endogenous Explanatory Variable Is Weak." *Journal of the American Statistical Association* 90 (430): 443–450.
- Budde, R., and L. Eilers. 2014. *Sozioökonomische Daten Auf Rasterebene: Datenbeschreibung Der microm-Rasterdaten, RWI: Materialien*. Vol. 77. Essen: Rheinisch-Westfälisches Institut für Wirtschaftsforschung.
- Centers for Disease Control and Prevention - National Center for Health Statistics. 2017. "Underlying Cause of Death 1999-2016" on CDK Wonder Online Database. <http://wonder.cdc.gov/ucd-icd10.html>. assessed 10 September 2018.
- Charlson, M. E., P. Pompei, K. L. Ales, and C. R. MacKenzie. 1987. "A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies. Development and Validation." *Journal of Chronic Diseases* 40 (5): 373–383. doi:10.1016/0021-9681(87)90171-8.
- Cutler, D. M. 2007. "The Lifetime Costs and Benefits of Medical Technology." *Journal of Health Economics* 26 (6): 1081–1100. doi:10.1016/j.jhealeco.2007.09.003.
- Cutler, D. M., and M. McClellan. 2001. "Is Technological Change in Medicine Worth It?" *Health Affairs* 20 (5): 11–29. doi:10.1377/hlthaff.20.5.11.
- Ford, E. S., U. A. Ajani, J. B. Croft, J. A. Critchley, D. R. Labarthe, T. E. Kottke, W. H. Giles, and S. Capewell. 2007. "Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980-2000." *The New England Journal of Medicine* 356 (23): 2388–2398. doi:10.1056/NEJMs053935.
- Fox, K. A. A., P. G. Steg, K. A. Eagle, S. G. Goodman, F. A. Anderson, C. B. Granger, M. D. Flather, A. Budaj, A. Quill, and J. M. Gore. 2007. "Decline in Rates of Death

- and Heart Failure in Acute Coronary Syndromes, 1999-2006.” *The Journal of the American Medical Association* 297 (17): 1892–1900. doi:10.1001/jama.297.17.1892.
- Freisinger, E., T. Fuerstenberg, N. M. Malyar, J. Wellmann, U. Keil, G. Breithardt, and H. Reinecke. 2014. “German Nationwide Data on Current Trends and Management of Acute Myocardial Infarction: Discrepancies between Trials and Real-life.” *European Heart Journal* 35 (15): 979–988. doi:10.1093/eurheartj/ehu043.
- GBE - Gesundheitsberichterstattung des Bundes (2015), “Krankheitskosten in Mio. € Für Deutschland (Primary Source: Statistisches Bundesamt, Krankheitskostenrechnung). Thematic Research: Kosten Herzinfarkt - Krankheitskosten Nach Alter Und Geschlecht - Document Type: Table” accessed 1 October 2018.
- Gowrisankaran, G., and R. J. Town. 1999. “Estimating the Quality of Care in Hospitals Using Instrumental Variables.” *Journal of Health Economics* 18 (6): 747–767. doi:10.1016/S0167-6296(99)00022-3.
- Hentschker, C. (2016), “From Dusk till Dawn are Nights a Dangerous Time for Hospital Admissions?”, unpublished.
- Imbens, G. W., and J. D. Angrist. 1994. “Identification and Estimation of Local Average Treatment Effects.” *Econometrica* 62 (2): 467–475. doi:10.2307/2951620.
- Keeley, E. C., J. A. Boura, and C. L. Grines. 2003. “Primary Angioplasty versus Intravenous Thrombolytic Therapy for Acute Myocardial Infarction: A Quantitative Review of 23 Randomised Trials.” *The Lancet* 361 (9351): 13–20. doi:10.1016/S0140-6736(03)12113-7.
- Khwaja, A., G. Picone, M. Salm, and J. G. Trogon. 2011. “A Comparison of Treatment Effects Estimators Using A Structural Model of AMI Treatment Choices and Severity of Illness Information from Hospital Charts.” *Journal of Applied Econometrics* 26 (5): 825–853. doi:10.1002/jae.1181.
- Krumholz, H. M., J. Herrin, L. E. Miller, E. E. Drye, S. M. Ling, L. F. Han, M. T. Rapp, et al. 2011. “Improvements in Door-to-balloon Time in the United States, 2005 to 2010.” *Circulation* 124 (9): 1038–1045. doi:10.1161/CIRCULATIONAHA.111.044107.
- Kumar, A., and M. Schoenstein. 2013. *Managing Hospital Volumes: Germany and Experiences from OECD Countries*. Paris: OECD Publishing.
- Mansky, T., U. Nimptsch, C. Winklmaier, K. Vogel, and F. Hellerhoff. 2011. *G-IQI German Inpatient Quality Indicators, Version 3.1: HELIOS Qualitätsindikatoren, IQM-Qualitätsindikatoren - Definitionshandbuch, Version 3.1, Datenjahr 2010*. Berlin: Universitätsverlag der TU Berlin.
- McClellan, M., B. J. McNeil, and J. P. Newhouse. 1994. “Does More Intensive Treatment of Acute Myocardial Infarction in the Elderly Reduce Mortality? Analysis Using Instrumental Variables.” *The Journal of the American Medical Association* 272 (11): 859–866. doi:10.1001/jama.1994.03520110039026.
- Microm Consumer Marketing. 2014. *Microm Datenhandbuch: Arbeitsunterlagen Für Microm MARKET & GEO*. microm GmbH, Neuß: microm GmbH.
- Microm Micromarketing-Systeme und Consult GmbH. 2015a. *Sozioökonomische Daten Auf Rasterebene: Kaufkraft*, Neuß: microm GmbH.
- Microm Micromarketing-Systeme und Consult GmbH. 2015b. *Sozioökonomische Daten Auf Rasterebene: Arbeitslosenquote*
- Microm Micromarketing-Systeme und Consult GmbH. 2015c. *Sozioökonomische Daten Auf Rasterebene: Einwohner*, Neuß: microm GmbH.
- Newhouse, J. P. 1992. “Medical Care Costs: How Much Welfare Loss?” *Journal of Economic Perspectives* 6 (3): 3–21. doi:10.1257/jep.6.3.3.
- Newhouse, J. P., and M. McClellan. 1998. “Econometrics in Outcomes Research: The Use of Instrumental Variables.” *Annual Review of Public Health* 19 (1): 17–34. doi:10.1146/annurev.publhealth.19.1.17.
- Okunade, A. A., and V. N. R. Murthy. 2002. “Technology as a ‘Major Driver’ of Health Care Costs: A Cointegration Analysis of the Newhouse Conjecture.” *Journal of Health Economics* 21 (1): 147–159. doi:10.1016/S0167-6296(01)00122-9.
- Rathore, S. S., J. P. Curtis, B. K. Nallamothu, Y. Wang, J. M. Foody, M. Kosiborod, F. A. Masoudi, E. P. Havranek, and H. M. Krumholz. 2009. “Association of Door-to-balloon Time and Mortality in Patients ≥ 65 Years with ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.” *The American Journal of Cardiology* 104 (9): 1198–1203. doi:10.1016/j.amjcard.2009.06.034.
- Ryen, L., and M. Svensson. 2015. “The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature.” *Health Economics* 24 (10): 1289–1301. doi:10.1002/hec.3085.
- Sanwald, A., and T. Schober. 2017. “Follow Your Heart. Survival Chances and Costs after Heart Attacks: An Instrumental Variable Approach.” *Health Services Research* 52 (1): 16–34. doi:10.1111/1475-6773.12509.
- Schwierz, C., and A. Wübker. 2010. “Determinants of Avoidable Deaths from Ischemic Heart Disease in East and West Germany.” *Journal of Public Health* 18 (4): 309–317. doi:10.1007/s10389-010-0314-1.
- Skinner, J. 2011. “Causes and Consequences of Regional Variations in Health Care.” In *Handbook of Health Economics: Volume 2*, edited by M. V. Pauly et al., 45–93. Amsterdam: Elsevier North-Holland.
- Smolina, K., F. L. Wright, M. Rayner, and M. J. Goldacre. 2012. “Determinants of the Decline in Mortality from Acute Myocardial Infarction in England between 2002 and 2010: Linked National Database Study.” *BMJ (Clinical Research Ed.)* 344 (jan25 2): 1–9. doi:10.1136/bmj.d8059.
- Soekhlal, R. R., L. T. Burgers, W. K. Redekop, and S. S. Tan. 2013. “Treatment Costs of Acute Myocardial Infarction in the Netherlands.” *Netherlands Heart Journal* 21 (5): 230–235. doi:10.1007/s12471-013-0386-y.
- Statistisches Bundesamt. (2017). “Todesursachen in Deutschland 2015”, Fachserie 12, Reihe 4, Wiesbaden.
- Steg, P. G., S. K. James, D. Atar, L. P. Badano, C. Blömström-Lundqvist, M. A. Borger, C. Di Mario, et al. 2012. “ESC Guidelines for the Management of Acute Myocardial

Infarction in Patients Presenting with ST-segment Elevation.” *European Heart Journal* 33 (20): 2569–2619.

Stukel, T. A., E. S. Fisher, D. E. Wennberg, D. A. Alter, D. J. Gottlieb, and M. J. Vermeulen. 2007. “Analysis of Observational Studies in the Presence of Treatment Selection Bias: Effects of Invasive Cardiac Management on AMI Survival Using Propensity Score and Instrumental Variable Methods.” *The Journal of the American Medical Association* 297 (3): 278–285. doi:10.1001/jama.297.3.278.

Wübker, A. 2007. “Measuring the Quality of Healthcare: The Connection between Structure, Process, and Outcomes of Care, Using the Example of Myocardial Infarction Treatment in Germany.” *Disease Management & Health Outcomes* 15 (4): 225–238. doi:10.2165/00115677-200715040-00004.

Appendix

Table A1: Regression results (instrument: differential time).

	OLS				IV			
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
PTCA	−0.1165*** (0.0023)	−0.0983*** (0.0025)	−0.1023*** (0.0023)	−0.1019*** (0.0023)	−0.0454*** (0.0100)	−0.0486*** (0.0088)	−0.0504*** (0.0089)	−0.0451*** (0.0098)
Age		0.0044*** (0.0001)	0.0045*** (0.0001)	0.0045*** (0.0001)		0.0049*** (0.0001)	0.0049*** (0.0001)	0.0049*** (0.0001)
Male		0.0010 (0.0012)	0.0008 (0.0012)	0.0012 (0.0012)		−0.0036** (0.0015)	−0.0037*** (0.0014)	−0.0037** (0.0015)
Admission reason: Emergency		0.0220*** (0.0018)	0.0205*** (0.0018)	0.0200*** (0.0018)		0.0207*** (0.0018)	0.0199*** (0.0018)	0.0197*** (0.0018)
Admission reason: Transfer		−0.0052 (0.0047)	−0.0084* (0.0044)	−0.0100** (0.0044)		−0.0048 (0.0043)	−0.0064 (0.0042)	−0.0079* (0.0041)
Non-ST-elevated MI		−0.1216*** (0.0018)	−0.1225*** (0.0018)	−0.1224*** (0.0018)		−0.1142*** (0.0022)	−0.1147*** (0.0023)	−0.1138*** (0.0023)
CCI: 1–2		0.0058*** (0.0017)	0.0051*** (0.0017)	0.0047*** (0.0017)		0.0089*** (0.0018)	0.0085*** (0.0018)	0.0084*** (0.0018)
CCI: 3–4		0.0230*** (0.0026)	0.0221*** (0.0026)	0.0216*** (0.0026)		0.0305*** (0.0029)	0.0301*** (0.0030)	0.0304*** (0.0030)
CCI: ≥5		0.0476*** (0.0036)	0.0465*** (0.0035)	0.0457*** (0.0034)		0.0586*** (0.0041)	0.0581*** (0.0041)	0.0584*** (0.0042)
Winter		0.0027** (0.0011)	0.0027** (0.0011)	0.0027** (0.0011)		0.0032*** (0.0011)	0.0032*** (0.0011)	0.0032*** (0.0011)
Weekend/holiday admission		0.0135*** (0.0012)	0.0134*** (0.0012)	0.0136*** (0.0012)		0.0154*** (0.0013)	0.0154*** (0.0013)	0.0156*** (0.0013)
Night admission		0.0062*** (0.0013)	0.0059*** (0.0013)	0.0060*** (0.0013)		0.0074*** (0.0013)	0.0072*** (0.0013)	0.0074*** (0.0013)
City		−0.0000 (0.0025)	0.0001 (0.0025)	0.0026 (0.0026)		−0.0014 (0.0024)	−0.0015 (0.0024)	0.0011 (0.0025)
Year 2006		0.0050*** (0.0014)	0.0053*** (0.0014)	0.0054*** (0.0014)		0.0033** (0.0014)	0.0035** (0.0014)	0.0034** (0.0014)
Year 2007		0.0111*** (0.0015)	0.0115*** (0.0015)	0.0116*** (0.0015)		0.0082*** (0.0015)	0.0084*** (0.0015)	0.0081*** (0.0016)
Ownership: not-for-profit			−0.0074*** (0.0026)	−0.0110*** (0.0027)			−0.0033 (0.0026)	−0.0080*** (0.0026)
Ownership: for-profit			0.0013 (0.0037)	−0.0015 (0.0038)			−0.0015 (0.0037)	−0.0045 (0.0038)
University hospital			0.0276*** (0.0049)	0.0261*** (0.0047)			0.0150*** (0.0052)	0.0123** (0.0049)
Minimum time to hospital				0.0002 (0.0001)				−0.0001 (0.0001)
Purchasing power per inhabitant				−0.0000 (0.0003)				−0.0006** (0.0003)
Unemployment rate				0.0009*** (0.0003)				0.0006** (0.0003)
Constant	0.1793*** (0.0021)	−0.1156*** (0.0056)	−0.1130*** (0.0059)	−0.1185*** (0.0098)	0.1451*** (0.0051)	−0.1700*** (0.0106)	−0.1687*** (0.0109)	−0.1648*** (0.0126)
Federal state indicators	No	No	No	Yes	No	No	No	Yes
R-squared	0.031	0.091	0.092	0.093	0.020	0.086	0.087	0.087
First-stage F-statistic					210.0809	281.6580	349.7454	352.8525
Test for endogeneity (p-value)					0.0000	0.0000	0.0000	0.0000
Number of patients	406,281	406,281	406,281	406,281	406,281	406,281	406,281	406,281
Number of hospitals	1,292	1,292	1,292	1,292	1,292	1,292	1,292	1,292

Notes: Clustered standard errors (at the hospital level) in parantheses; * p < 0.10, ** p < 0.05, *** p < 0.01.




Figure A1. Differential time 2007

Appendix B Background information

Cardiovascular diseases are the most frequent cause of death in Germany and other developed countries. Within this group AMI patients have a high share of deaths (Freisinger et al., 2014). In recent decades, however, a considerable reduction in AMI mortality rates can be observed in industrial countries (Ford et al., 2007; Fox et al., 2007; Smolina et al., 2012; Wübker, 2007). Public health and medical literature attributes these improvements to a reduction of classical risk factors like smoking or hypertension or by better secondary prevention (e.g. long-term drug therapy with statins, aspirin, etc.) (Ford et al., 2007; Fox et al., 2007; Wübker, 2007). However, improved AMI treatment like the expanded use of REVAS is considered as main cause for this development (Ford et al., 2007; Wübker, 2007).

Additionally, it is also plausible that the REVAS techniques itself have improved. This is reflected in medical guidelines. In

1987, i.e. the year of the data from the study of McClellan et al., McClellan et al. REVAS was rarely used on the first day of hospital admission. This has changed. It is now recommended to perform REVAS as soon as possible, i.e. within 12 hours of symptoms' onset or rather within 2 hours from the first medical contact (Steg et al., 2012). This more timely use is strongly associated with lower mortality rates (Krumholz et al., 2011; Rathore et al., 2009).

The advantage of REVAS over conservative AMI treatment has been documented in several clinical trials. In general, randomized controlled trials (RCTs) find that patients treated with REVAS have better outcomes than patients treated with thrombolytic drugs (Keeley et al., 2003). However, RCTs have been criticized because although they have high internal validity, they have shortcomings in external validity (Newhouse and McClellan, 1998). This is because RCTs are often executed under optimal conditions unachievable in the real world. Moreover, RCTs focus on narrow treatment

comparisons and special patient populations, therefore, their results are often insufficient to shape health policy (McClellan et al., 1994). With administrative data it is possible to detect the effect of REVAS on mortality in the whole population.

In recent years, REVAS has been increasingly used in Germany and in other developed countries. In Germany, the application of REVAS more than doubled between 1996 and 2004 (Schwierz and Wübker, 2010). About 48.1% of AMI patients were treated with PTCA methods in Germany in 2009 (Freisinger et al., 2014). Germany is first in the number of PTCAs per 100,000 inhabitants and second for CABG amongst OECD countries (Kumar and Schoenstein, 2013). At the same time, large regional variation occurs within Germany (Kumar and Schoenstein, 2013). Figure B1 illustrates that the share of PTCA procedures for AMI treatment is below 35% in some regions, for example in parts of west

Rhineland-Palatinate or parts of Lower Saxony, but already above 65% in others, for example in east Hesse and parts of Baden- Württemberg.

AMI is of increasing economic importance. For example, € 1.40 billion were spent on heart attack treatment in Germany in 2004, whereas by 2008 the total was already € 1.87 billion (GBE, 2015). Annual growth in real terms was about 5.5%. Increasing AMI costs cannot be explained by a rising number of heart attacks, because AMI overall incidence and AMI hospital incidence remained relatively constant in recent years (Freisinger et al., 2014). Similar trends of increasing heart attack spending have been observed in other developed countries, like the US. Cutler and McClellan (2001) suggest that technological change, i.e. the extension of REVAS methods to more patients, is the main reason for the increasing costs.




Figure B1. Share of PTCA patients 2007